At a glance
ClinicalIndex Comparison RecordN/ACompleted· 540 enrolled
Drug / intervention
HeartMate 3device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating the HeartMate 3™ in a Post-Market Approval Setting: The HeartMate 3 Registry (ELEVATE™)
In Brief
An observational study evaluating HeartMate 3 for Heart Failure and 2 related conditions. Completed, enrolled 540 participants across 26 sites in 11 countries.
Detailed Summary
Evaluate real-world experience of HeartMate 3 (HM3) in post-approval setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Czechia, Denmark, Germany, Israel, Italy, Kazakhstan, Netherlands, Poland, Singapore, United Kingdom
CollaboratorsThoratec Europe Ltd, Thoratec Corporation
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartOct 2015
Primary CompletionFeb 2019
Study CompletionFeb 2022
TodayJul 2026
First PostedJul 15, 2015
Enrollment StartOct 13, 2015
Primary CompletionFeb 1, 2019
Study CompletionFeb 28, 2022
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 11.0 years ago
Interventions
HeartMate 3device
Any patient that is determined to meet the HM3 commercially approved labelling indication and that is implanted with the HM3